Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Gastroparesis
Interventions
DRUG

Nizatidine

Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

DRUG

Lisinopril

Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

DRUG

Placebo

Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.

Trial Locations (2)

55905

Mayo Clinic in Rochester, Rochester

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

National Center for Research Resources (NCRR)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Adil Bharucha

OTHER

NCT02232308 - Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects | Biotech Hunter | Biotech Hunter